<DOC>
	<DOCNO>NCT01105117</DOCNO>
	<brief_summary>This open-label , non-randomized extension study AC-066A401 . The study assess safety tolerability ACT-385781A Flolan ( epoprostenol sodium ) providing mean continue treatment end participation study AC-0066A401 .</brief_summary>
	<brief_title>Epoprostenol Injection Pulmonary Arterial Hypertension - Extension AC-066A401</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>1 . Signed informed consent prior initiation studymandated procedure 2 . Patients complete participation study AC066A401 3 . Patients obtain authorization commercial ACT385781 Flolan time end participation study AC066A401 1 . Patients prematurely discontinue study drug study AC066A401 2 . Patients continue treatment either ACT385781 Flolan longer consider appropriate 3 . Known hypersensitivity investigational drug comparative drug drug class , excipients 4 . Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease 5 . Known concomitant lifethreatening disease life expectancy &lt; 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>EPITOME-1</keyword>
</DOC>